Overview Heavy Elements (PSI) Development of fast chemical methods for the investigation of superheavy elements. We perform radiochemical studies with the heaviest elements of the periodic table. This research focuses on the investigation of deviations of chemical properties induced by the high nuclear charge in the atoms of the superheavy elements. The developed methods are instrumental to the discovery of new isotopes of superheavy elements and to the determination of their nuclear decay properties. Isotope and Target Chemistry ITC (PSI) Investigation and exploitation of activated material. Isotope and Target Chemistry (ITC) is a research group that deals not only with the study of the radioactive content of activated material and the physico-chemical behaviour of selected radionuclides therein, but is also focused on separation of rare exotic radionuclides needed in different scientific research fields like astrophysics, environmental research, fundamental nuclear physics and others. Development of radionuclides for innovative radiopharmaceuticals. Using PSI's cyclotrons and spallation neutron source (SINQ), this joint group of LRC and CRS provides novel, commercially not available radionuclides for future diagnosis and therapy of cancer, which, subsequently, are tested in pre-clinical trials.
Heavy Elements (PSI) Development of fast chemical methods for the investigation of superheavy elements. We perform radiochemical studies with the heaviest elements of the periodic table. This research focuses on the investigation of deviations of chemical properties induced by the high nuclear charge in the atoms of the superheavy elements. The developed methods are instrumental to the discovery of new isotopes of superheavy elements and to the determination of their nuclear decay properties.
Isotope and Target Chemistry ITC (PSI) Investigation and exploitation of activated material. Isotope and Target Chemistry (ITC) is a research group that deals not only with the study of the radioactive content of activated material and the physico-chemical behaviour of selected radionuclides therein, but is also focused on separation of rare exotic radionuclides needed in different scientific research fields like astrophysics, environmental research, fundamental nuclear physics and others.
Development of radionuclides for innovative radiopharmaceuticals. Using PSI's cyclotrons and spallation neutron source (SINQ), this joint group of LRC and CRS provides novel, commercially not available radionuclides for future diagnosis and therapy of cancer, which, subsequently, are tested in pre-clinical trials.
